The United States joined 21 other trading nations in eliminating tariffs on pharmaceutical items.
The United States joined 21 other trading nations in eliminating tariffs on pharmaceutical items, including products for the treatment of breast cancer, AIDS, diabetes, asthma and Parkinson's disease.
The update, which took effect on July 1, follows more than two years of industry and government efforts and will add at least 642 new chemical and bulk drug ingredients to the list of more than 8,000 pharmaceutical products that may be traded free of import tariffs.
All 15 member states of the European Union, the Czech Republic, Japan, Norway, the Slovak Republic and Switzerland participated in the initiative, which includes both finished pharmaceutical products and related chemical intermediaries. In addition, countries participating in the agreement have agreed to update the list of covered products at least once every three years so that newly developed products can be added.
"The elimination of tariffs on these products will further expand U.S. overseas market access opportunities in Europe and Asia and will help reduce costs and improve productivity in this leading high-technology industry," said U.S. trade representative Charlene Barshefsky. "Consumers in the United States and around the world will benefit from lower pharmaceutical prices and, potentially, wider product choices."
According to the Pharmaceutical Research and Manufacturers of America, the Washington-based lobbying arm of the pharmaceutical industry, the tariff elimination package will also free up funds for additional research and development of new drugs.
"This update will benefit the world's patients by eliminating an unnecessary tax on research and development and [by] freeing up more funds to discover and develop new medicines," said PhRMA president Alan F. Holmer. "It costs an average of $500 million to research and bring to market just one new medicine, and U.S. companies will invest more than $24 billion in R&D this year alone." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.